BC Week In Review | Sep 9, 2013
Clinical News

FF284: Phase I started

Debiopharm began an open-label, international Phase I trial to evaluate once-daily oral Debio 1347 in patients with advanced solid tumors who have an alteration of the FGFR 1, 2 or 3 genes. An expansion phase...
BC Week In Review | Jan 14, 2013
Company News

Debiopharm, Chugai deal

Chugai granted Debiopharm exclusive, worldwide rights to develop and commercialize FF284 ( Debio 1347 ), an oral small molecule against an undisclosed target in preclinical testing to treat cancer. Debiopharm also received a non-exclusive license to...
Items per page:
1 - 2 of 2